J. Helen Cross

Jul 31, 2024 | onlinelibrary.wiley.com | J. Helen Cross

EDITORIAL Thank you to the outgoing editor-in-chief of Epilepsia, Michael Sperling: International League Against Epilepsy J. Helen Cross,  Corresponding Author J. Helen Cross University College London, Great Ormond Street Institute of Child Health, London, UK International League Against Epilepsy, Washington, District of Columbia, USA Correspondence J. Helen Cross, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.

Jul 4, 2024 | onlinelibrary.wiley.com | Elaine C. Wirrell |Lieven Lagae |Ingrid E. Scheffer |J. Helen Cross

Fenfluramine (FFA) is an antiseizure medication (ASM) used in the treatment of seizures associated with Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS). FFA is initiated at 0.2 mg/kg/day but speed of titration may depend on age, weight, and concomitant medications. FFA is generally well-tolerated and associated with a low risk of clinically relevant drug–drug interactions, which are often observed with polypharmacy.

Mar 15, 2024 | emjreviews.com | J. Helen Cross |Elaine C. Wirrell

IntroductionDS, which has a prevalence of 1.5−6.5/ 100,000,1-5 is predominantly due to variants in the gene SCN1A affecting the sodium channel.6 Onset is usually in the first year of life, with prolonged and recurrent seizures. Further seizure types emerge, including myoclonic, absence, and focal seizures with impaired awareness, which persist into adulthood. Prior to seizure onset, development is usually typical, or with only minor delay.

Mar 8, 2024 | onlinelibrary.wiley.com | J. Helen Cross |Arturo Benítez |Jeannine Roth |J. Scott Andrews

Reducing the high clinical symptom burden of LGS could increase quality of life of patients and caregivers LGS is associated with high direct costs due to health care resource use and medications; data on indirect costs are lacking Pharmacoresistance is common, and most individuals with LGS require polytherapy and changes to treatment over time There is an unmet need for treatments that address the nonseizure symptoms of LGS There is a need for a greater understanding of and better...

Aug 6, 2023 | onlinelibrary.wiley.com | Joseph Sullivan |Lieven Lagae |J. Helen Cross |Orrin Devinsky

RESEARCH ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/epi.17737. Abstract Objective To assess the safety and efficacy of fenfluramine in the treatment of convulsive seizures in patients with Dravet syndrome.